We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
As you can see from the chart above the percentage of shares that are sold short for Intellia Therapeutics has grown since its last report. This does not mean that the stock is going to fall in ...
Hosted on MSN16d
Morgan Stanley Downgrades Intellia Therapeutics (NTLA)Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...
Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ...
A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...
Today, a brief rundown of news involving Intellia Therapeutics and ArriVent BioPharma, as well as updates from Atara Biotherapeutics, Amylyx Pharmaceuticals and InnoCare Pharma that you may have ...
NEW YORK – Intellia Therapeutics on Wednesday said it has dosed the first hereditary angioedema patient within the Phase III HAELO trial of the investigational in vivo CRISPR-based gene-editing ...
Has Fulham suddenly turned into a golf course? No, those electric carts are Yo-Gos. Ten of the bright yellow golf-cart style buggies are being trialled until October as part of a micro mobility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback